Mesoblast shares push higher on strong sales update

Sales are growing for this biotech. Let's see what it reported today.

Key points
  • Mesoblast shares increased by over 1% following positive updates on quarterly sales and strong demand for its newly FDA-approved product, Ryoncil, projecting over US$30 million in revenue for the December quarter.
  • Ryoncil's FDA approval is a transformational milestone for Mesoblast, marking a significant shift from development to commercialisation, with extensive payor coverage now in place across the U.S.
  • The company plans to leverage learnings from Ryoncil's success to pursue additional FDA approvals in cardiovascular and back pain treatment markets, reinforcing its long-term growth strategy.

Mesoblast Ltd (ASX: MSB) shares are in the spotlight on Tuesday.

In morning trade, the allogeneic cellular medicines developer's shares are up over 1% to $2.36.

This follows the release of the company's annual general meeting update and quarterly sales guidance.

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.

Image source: Getty Images

What did the company announce?

Let's start with its sales performance in the current quarter.

According to the release, Mesoblast's sales are expected to be up strongly quarter on quarter thanks to increasing demand for its Ryoncil (remestemcel-L-rknd) product.

For the quarter ended 31 December, management revealed that it expects gross revenue of more than US$30 million from sales of Ryoncil (remestemcel-L-rknd). This represents an increase of 37% on the US$21.9 million in gross revenue that was record from Ryoncil in the prior quarter ended 30 September 30.

What else?

At its annual general meeting, management spoke very positively about Ryoncil and how its approval by the US FDA has transformed the company forever. The company's chair, Jane Bell, said:

The FDA approval of Ryoncil is not simply a regulatory milestone: it is a turning point in our transition from development to commercialization, and a powerful validation of Mesoblast's scientific platform, manufacturing rigor, and clinical strategy.

The commercial launch of Ryoncil has been executed flawlessly with strong uptake to date and growing sales, which have exceeded our expectations. We are very pleased with the commercial and government reimbursement that is now in place, as we ensure that all children with this devastating disease have access to our life-saving treatment with payor coverage now extending to over 260 million lives in the U.S. as well as successful onboarding and physician adoption.

Bell also highlights that the first approval could be just the start of many more in the future. She highlights that Mesoblast has its eyes on the cardiovascular and back pain markets, adding:

Achieving a first FDA approval and demonstrating successful product commercialization provides important validation for our whole strategy and value chain of our technology platforms. The learnings from Ryoncil are being adapted to the rest of the company's pipeline and will hold us in good stead as we work towards further FDA approvals for our cardiovascular and back pain indications for our second-generation stromal cell technology platform.

Mesoblast shares have been strong performers over the past 12 months. During this time, they are up almost 40%. This compares to a gain of just 1.3% from the ASX 200 index over the same period.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »